Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Formula-02: Disitamab Vedotin + BCG vs BCG in HER2-high high-risk NMIBC
ChiCTR2600117601Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of disitamab vedotin in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 2-year event-free survival rate (2y-EFS). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2600117601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117601.